Neutrolin Versus Heparin for Locking Hemodialysis Catheters

• Status: Unknown status
• Trial end date: 2021-04-04
• Target enrollment: 0
• Participant gender: All

Summary

Hemodialysis catheter related bacterial infections represent a major cause of mortality and morbidity in the hemodialysis population. Several locking agents had been tried with variable degree of success but not without side effects.

Neutrolin catheter locking agent comprises of heparin,citrate and trauolidine that had been studied in a prospective study in Germany, and it demonstrated a very good result in terms of reducing the catheter related infections and thrombosis.

This study is a multi-center, double-blind RCT comparing the hemodialysis catheter locking solution Neutrolin with heparin in reducing the rate of catheter related bacterial infection and thrombosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Abdullah International Medical Research Center
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• New hemodialysis catheter

• Subject who will need chronic hemodialysis at least twice/week

• Subject likely to require for at least 120 days

• Subject or relative is likely to understand the nature of the study and sign the consent

• Age 18 years and older

Exclusion Criteria:

• Subject with unstable malignancy

• Subject with liver cirrhosis with encephalopathy

• Subject know to have allergy to heparin, citrate or traoulidine

• Documented history of arterial thrombosis or known to have hypercoagulable state

• Subjects with active skin infections and ulcers